A study conducted in Rhode Island suggests that individuals with opioid use disorder may require higher doses of the medication buprenorphine to improve treatment retention, particularly in the face of the fentanyl crisis. The study found that patients prescribed a daily dose of 24 milligrams (mg) of buprenorphine were 20% more likely to remain in treatment compared to those prescribed the recommended 16 mg dose. The findings highlight the need to re-evaluate dosing guidelines for buprenorphine in order to optimize treatment and help individuals with opioid use disorder achieve recovery.
A study funded by the National Institute on Drug Abuse (NIDA) suggests that higher doses of buprenorphine may improve retention in treatment for opioid use disorder. The study, conducted in Rhode Island from 2016 to 2020, found that individuals prescribed a lower dose of buprenorphine were 20% more likely to discontinue treatment compared to those on a higher dose. The findings highlight the need to reevaluate clinical guidelines for opioid addiction treatment, particularly in the context of the fentanyl crisis. The study supports the growing evidence that higher doses of buprenorphine are safe and effective in reducing opioid use and improving treatment outcomes.
